People

Kelly Girskis was publicly named by Arkuda Therapeutics as Board Member. Her archived2024 issuer biography identifies an abrdn investment-director role following the October2023 Tekla transition, and previous Tekla research work covering private and public biotech. Her background includes SVB Leerink and Ascentia Asset Management and neuroscience training. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Robert Benson is an investment director on abrdn’s healthcare team in its2026 biography, having joined in2023 from Tekla after seven years. At Tekla he served as vice president, performing fundamental and quantitative portfolio analysis and research in small/midcap biotechnology and diagnostics. Previously he held quantitative investment research roles at State Street Global Advisors and Putnam Investments. His published education includes a Berkeley MS in Financial Engineering.

Jason Akus is Head of Healthcare Investments at abrdn Inc., succeeding Daniel Omstead as lead of the four former Tekla healthcare funds in June2024. He joined the predecessor adviser in2001 and formerly served as Tekla senior vice president of research. He holds a Tufts BS in Mathematics and MD/MBA. His work includes investment due diligence in biotechnology, medical devices and diagnostics; the 2026 own biography and current healthcare fund page identify his current affiliation, distinct from historical Tekla employment.

Portfolio manager at Woodline Partners covering consumer businesses, including health and wellness. The firm's published profile describes earlier healthcare investing and investment banking experience and a Wharton economics degree.

Chief financial officer of Woodline Partners, identified as Christopher Michael Todd in regulatory filings. A senior finance executive of the investment management business.

Chief compliance officer of Woodline Partners, identified as Erin Sian Mullen in regulatory filings. Oversees compliance within the investment adviser.

Chief operating officer of Woodline Partners, identified as Matthew Paul Hooker in regulatory filings. A senior leader responsible for the investment management business's operations.

Co-chief investment officer of Woodline Partners, identified as Karl Heinz Kroeker in regulatory filings. A senior investment leader and principal of the investment management business.

Co-founder and co-chief investment officer of Woodline Partners, identified as Michael Clifford Rockefeller in regulatory filings. Oversees investing and firm strategy and has discussed the firm's biotechnology and pharmaceutical research approach.

Clinical advisory board member of ProMIS Neurosciences. Researcher associated with the University of Gothenburg and University College London, specializing in fluid biomarkers for neurological disorders. Henrik Zetterberg is ALZpath’s Distinguished Scientific Advisor. He researches fluid biomarkers for neurological disease and holds neurochemistry appointments at the University of Gothenburg and University College London. Henrik Zetterberg is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Professor of Neurochemistry and Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and Clinical Chemist at Sahlgrenska University Hospital. This is a foundation governance or honorary affiliation, not an assertion of operating employment. Henrik Zetterberg is listed by Vesper Bio as Scientific Advisor. Neurochemistry and fluid-biomarker researcher affiliated with Gothenburg/UCL; current Vesper scientific-advisory capacity is source-qualified separately from existing company and foundation affiliations.

Clinical advisory board member of ProMIS Neurosciences. University of California, San Francisco researcher associated with the Alzheimer’s Disease Neuroimaging Initiative and Brain Health Registry, studying brain imaging and dementia. Michael Weiner is an ALZpath scientific adviser and UCSF professor emeritus. He leads the Alzheimer’s Disease Neuroimaging Initiative and Brain Health Registry, with long-standing research in MRI and neurodegenerative disease.

Scientific advisory board member of ProMIS Neurosciences. University of British Columbia researcher studying Alzheimer’s disease, traumatic brain injury and fluid biomarkers.

Scientific advisory board member of ProMIS Neurosciences. King’s College London researcher studying Down syndrome, Alzheimer’s disease, biomarkers and neuropsychiatry.

Scientific advisory board member of ProMIS Neurosciences. McGill physician-scientist studying the genetics of neurological disease, with medical training at Ottawa and a doctorate from Harvard.

Scientific advisory board member of ProMIS Neurosciences. University of California, San Diego physician-scientist studying Down syndrome and Alzheimer’s disease.

Scientific advisory board member of ProMIS Neurosciences. Physician-scientist researching protein misfolding and its relationship to psychiatric and neurological disorders.

Scientific advisory board member of ProMIS Neurosciences. Researcher studying RNA splicing and antisense approaches to genetic and neurological disorders.

Scientific advisory board member of ProMIS Neurosciences. McGill neurologist and researcher studying brain imaging, movement disorders and Parkinson’s disease.

Scientific advisory board member of ProMIS Neurosciences. Neurologist associated with the Toronto Memory Program, specializing in dementia care and clinical trials.

Independent director of ProMIS Neurosciences and co-founder of Oliver Wyman. Management consultant and business leader with previous experience at Booz Allen.

Chairman and co-founder of ProMIS Neurosciences. Biotechnology entrepreneur with leadership experience at Genzyme, Adheris and Dart and a background in healthcare business development.

Lead independent director of ProMIS Neurosciences. Intellectual property adviser with experience in biotechnology and pharmaceutical patent strategy, including at Genzyme and Sanofi.

Josh Mandel-Brehm serves as President & Chief Executive Officer at CAMP4 Therapeutics. Biotechnology executive with prior business development experience at Biogen and Genzyme and entrepreneurship experience with Polaris Partners; also serves on the ProMIS Neurosciences board.

Independent director of ProMIS Neurosciences. Healthcare investment professional associated with Ally Bridge public equity investing and portfolio management.

Chief physics officer of ProMIS Neurosciences and University of Alberta researcher. Works on computational approaches to protein structure, molecular biology and therapeutic discovery.

Chief commercial officer of ProMIS Neurosciences, appointed effective October 5, 2026. Biotechnology executive with experience in neuroscience commercialization and market preparation.

Chief development officer of ProMIS Neurosciences. Life sciences executive with experience translating research into therapeutic development programs.

Chief financial officer of ProMIS Neurosciences and founding managing director of Danforth Advisors. Provides financial leadership to life sciences companies through advisory and executive engagements.

ProMIS Neurosciences co-founder and chief scientific officer, board director and scientific advisory board co-chair. Physician-scientist studying misfolded proteins and neurodegenerative diseases.

Chief medical officer of ProMIS Neurosciences. Neurologist and biotechnology executive with experience in neuroscience drug development and clinical research.

Consultant on Great Point Partners' CEO Advisory Board with healthcare services leadership experience. Previously led Autism Learning Partners and Kindred Healthcare's hospital division. Studied at San Francisco University and Golden Gate University, according to the firm's biography.

Industrial pharmacist, pharmaceutical engineer and consultant on Great Point Partners' CEO Advisory Board. Previously led Clinical Supplies Management's European operations and B&C Group and has experience with clinical research logistics and industry associations. Graduated from the Catholic University of Louvain.

Physician and healthcare executive serving as a consultant on Great Point Partners' CEO Advisory Board. Previously held marketing, strategy and corporate development leadership at Hill-Rom, Hospira and GE Healthcare. Holds Michigan economics, biomedical engineering and medical degrees.

Consultant on Great Point Partners' CEO Advisory Board with healthcare technology strategy and company leadership experience. Previously worked at Strata Decision Technology, Applied Pathways, Sg2 and Allscripts and co-founded MediRegs. Holds a Michigan economics degree.

Consultant on Great Point Partners' CEO Advisory Board with clinical supply and pharmaceutical services leadership experience. Previously led Clinical Supplies Management and held development and clinical services leadership at Catalent. Holds Ohio State finance and international business degrees.

Consultant on Great Point Partners' CEO Advisory Board with biological, medical device and drug manufacturing experience. Previously led Bionova, MaSTherCell and Cytovance and held operations roles at Immucor and Aronex. Holds a biology degree and studied executive business administration at Texas A&M.

Consultant on Great Point Partners' CEO Advisory Board with pharmaceutical manufacturing and leadership experience. Previously led Eon Labs and the Sandoz division of Novartis and chaired portfolio company boards. Holds a Ludwig Maximilian University of Munich PhD.

Consultant on Great Point Partners' CEO Advisory Board with healthcare payment and services leadership experience. Previously led business development at Medlogix and worked at Sedgwick. Holds a Hofstra public accounting degree.

Member of Great Point Partners' CEO Advisory Board with experience leading healthcare and veterinary services businesses. Previously led Advantia Health, Heart + Paw and Banfield Pet Hospital. Holds Miami University and Harvard degrees. The advisory board provides consulting support.

Great Point Partners executive assistant, joining in 2006 after administrative roles at Amaranth Advisors and Pequot Capital Management. Holds a Purchase College fine arts degree in voice and opera performance.

Great Point Partners executive assistant, joining in 2021. Previously supported investment professionals at A&M Capital Opportunity and Durham Asset Management.

Great Point Partners investor relations and event coordinator, joining at the firm's inception in 2003. Previously supported investment technology leadership at J. H. Whitney. Graduated from York College of Pennsylvania.

Great Point Partners head of business development and investor relations, joining in 2026. Previously led investor relations at Rock Springs Capital and business development at QVIDTVM, with earlier roles at Stephens, William Blair and Thomas Weisel. Holds a Santa Clara political science degree.

Great Point Partners assistant vice president of finance, joining in 2012 and supporting fund reporting and operations. Previously worked at SS&C GlobeOp. Holds Lehigh finance and marketing degrees and an NYU MBA.

Great Point Partners general counsel and chief compliance officer, joining in 2019. Previously worked in legal and compliance at Irving Place Capital and as a lawyer at Davis Polk and Paul Weiss. Holds NYU law and Yeshiva accounting degrees and a CPA credential.

Great Point Partners chief accounting officer, joining in 2007 and managing finance and operations across its funds and management company. Previously an audit associate at PwC. Holds a Binghamton accounting degree and CPA credential.

Great Point Partners chief operating officer and chief financial officer, joining in 2010. Previously led finance and operations at MayerCap and ReachCapital and worked at Ziff Brothers and Deloitte. Holds an Emory business degree and CFA, CPA and financial risk management credentials.

Great Point Partners analyst, joining in 2025 after studying biological and agricultural sciences at Cornell. Previously researched biotechnology companies as a UBS summer analyst and worked at the USDA.

Great Point Partners public equity analyst, joining in 2025 after biotechnology research at TD Cowen. Holds a University of Pennsylvania undergraduate degree and Weill Cornell medical degree.

Great Point Partners analyst, joining in 2026 after studying economics at the University of Virginia. Previously evaluated healthcare and business services investments at Interlock Equity.

Great Point Partners public equity analyst, joining in 2024 after biotechnology research at Guggenheim Securities. Holds a University of Rhode Island pharmacy doctorate and Indiana University MBA.

Great Point Partners analyst, joining in 2025. Holds a Columbia neuroscience and behavior degree, with earlier work at Brean Capital and psychiatric research at Vanderbilt.

Great Point Partners senior analyst on its public equity team, joining in 2025. Previously evaluated biotechnology therapeutics at Braidwell and conducted preclinical research at Regeneron. Holds a University of Pennsylvania cell and molecular biology PhD and completed pharmacology postdoctoral research there.

Great Point Partners associate, joining in 2024 after studying philosophy, politics and economics at the University of Pennsylvania. Previously interned at Sculptor Capital Management.

Great Point Partners associate, joining in 2024 after medical device outsourcing investment banking work at Piper Sandler. Holds a Macalester economics and political science degree.

Great Point Partners associate, joining in 2023. Holds a Cornell hotel administration degree with real estate and sustainability study. Previously covered healthcare IT and software during an internship at Aldrich Capital Partners.

Great Point Partners associate, joining in 2023 after graduating from Notre Dame with a finance degree. Previously interned at private equity firm Tyree & D'Angelo Partners.

Great Point Partners associate, joining in 2025 after corporate development work at Optum and advisory work at Stanwich Advisors. Holds a Williams economics degree and Dartmouth MBA.

Great Point Partners associate, joining in 2026 after healthcare investment banking at TripleTree and consulting work at ettain group and Accenture. Holds a University of Virginia public policy and leadership degree.

Great Point Partners senior associate, joining in 2022. Holds a Wake Forest finance degree and previously interned at WCM Investment Management.

Great Point Partners vice president, joining in 2021 after healthcare investment banking at SVB Leerink and valuation work at PwC. Holds Lehigh degrees in finance and mechanical engineering.

Great Point Partners vice president, joining in 2026. Previously invested in healthcare technology and services at Brighton Park Capital and Great Hill Partners. Holds a Michigan business degree and Wharton MBA.

Great Point Partners vice president, joining in 2022 after investing in healthcare services and technology at Council Capital and working in EY investment banking. Holds a Brigham Young University finance degree.

London-based Great Point Partners vice president for business development, joining in 2022 and focusing on European opportunities. Previously worked at Vitruvian and Partners Group, including pharmaceutical services investing. Holds an Oxford medicine degree.

UMass Medical School physician-scientist and RNA therapeutics researcher with a long-standing focus on Huntington’s disease.

RNA therapeutics researcher who developed oligonucleotide technology and RNA interference drug design at UMass Medical School.

Biotechnology finance and operations executive; Atalanta’s current board directory describes him as its former CFO / COO. Previously held these roles at Jnana Therapeutics and was CFO of Dicerna Pharmaceuticals.

Healthcare venture investor and F-Prime Capital president and managing partner with previous biotechnology management and research experience. Serves as Board Member at Paradigm Health, according to its current team directory.

Physician and biotechnology entrepreneur who co-founded Comanche Biopharma and The Medicines Company. Distinct from the Blitzscaling Ventures investor Scott Johnson.

Research leader with experience in neurological disease and gene editing, including scientific leadership at Affinia Therapeutics, Editas Medicine and Bristol Myers Squibb.

Biotechnology business development executive with gene therapy partnering experience at Spark Therapeutics and Novartis.

Physician-scientist specializing in movement disorders, neurogenetics and translational gene therapies; previously led gene therapy research at Spark Therapeutics.

Drug development executive with regulatory approval experience across infectious disease, dermatology and central nervous system therapies.

RNA interference and oligonucleotide research leader; previously Dicerna chief scientific officer and head of its research unit at Novo Nordisk.

Biotechnology executive who co-founded and led Jnana Therapeutics through clinical proof of concept and its acquisition by Otsuka.

Great Point Partners senior vice president and head of business development, joining in 2023. Previously led business development at Windham Venture Partners and corporate development at Science Exchange, and co-founded FourSight Capital Partners. Holds a West Virginia University engineering degree.

Great Point Partners principal, joining in 2016 after investing at General Atlantic and healthcare investment banking at Goldman Sachs. Holds a Dartmouth economics degree and Wharton MBA, with experience in healthcare services and pharmaceutical infrastructure investments.

London-based Great Point Partners principal, joining in 2022 after European middle market private equity work at RoundShield and Waterland. Holds economics degrees from Trinity College Dublin and the London School of Economics.

Great Point Partners principal, joining in 2015 and working on biopharmaceutical services and healthcare technology investments. Holds Notre Dame accounting and finance degrees, with earlier internships in investment banking and financial due diligence.

Great Point Partners principal, joining in 2016 after healthcare investment banking work at Stifel. Has experience with healthcare services and biotechnology manufacturing investments. Holds an Emory business degree specializing in finance and marketing.

Great Point Partners managing director, joining in 2007 after healthcare investment banking work at Cowen. Has experience with healthcare services, clinical supply and pharmaceutical services investments. Holds a Columbia economics degree.

Great Point Partners managing director and co-portfolio manager of its BioMedical Value Fund strategy. Joined in 2015 following healthcare investment banking work at Guggenheim Securities. Holds a Cambridge pharmacology master's degree and Princeton molecular biology degree.

Founder and managing partner of Great Point Partners, established in 2003, and co-portfolio manager of its BioMedical Value Fund strategy. Previously a general partner leading healthcare investments at J. H. Whitney. Has experience investing in biotechnology, medical services and neurophysiological monitoring. Holds Boston University undergraduate and medical degrees and a Harvard MBA.

Neurogene board director and physician-scientist with experience in clinical drug development. Neurogene's current biography identifies her AbCellera chief medical officer appointment in September 2025, following earlier medical leadership at Metagenomi, Maze, Prothena and BioMarin. Holds UCSF medical, Berkeley bioengineering PhD and Dartmouth engineering degrees.

Neurogene board director with biotechnology commercial and operations experience. Neurogene's current biography identifies his Scholar Rock chief operating officer appointment in April 2025, following earlier argenx and Alexion leadership. Holds a Florida State marketing degree.

Neurogene board director and independent consultant for biopharmaceutical companies. Previously a Samsara BioCapital partner from October 2017 through April 2025, with earlier investing roles at Sofinnova and Novo and research at Roche focused on psychiatric and neurodegenerative disease targets. Holds Wake Forest pharmacology, Kellogg MBA and Connecticut College degrees.

Neurogene board director with gene therapy manufacturing and quality expertise. Previously led global manufacturing and technical operations at BioMarin and held quality roles at Genentech. Neurogene's current biography also identifies him as a Samsara BioCapital venture partner. Holds CUNY biochemistry degrees and a Regis MBA. Robert Baffi is listed by Samsara BioCapital as Venture Partner. His manufacturing and technical-operations experience includes two decades at BioMarin and earlier quality work at Genentech. He supports biotechnology product development and manufacturing readiness.

Neurogene senior vice president and general counsel. Previously interim chief executive officer and general counsel of Neoleukin Therapeutics, leading its December 2023 merger with Neurogene. Earlier served as deputy general counsel at HomeStreet and as a partner at Davis Wright Tremaine.

Neurogene senior vice president of technical operations, joining in 2018 and leading development of its gene therapy process, analytical and manufacturing capabilities. Previously headed Lonza's Houston manufacturing facility and held gene therapy quality roles at Introgen and Vivante GMP Solutions. Holds a Texas A&M biomedical science degree.

Neurogene senior vice president for regulatory affairs, quality assurance and quality control. A pediatric gastroenterologist and rare disease drug development specialist, previously leading regulatory affairs at Amicus and serving as an FDA division deputy director. Holds Columbia and Mount Sinai degrees.

Neurogene chief commercial officer with experience building commercial organizations for rare disease therapies. Previously senior vice president and general manager for North America at Avidity Biosciences and chief commercial officer at Marinus Pharmaceuticals. Also held leadership roles at Alexion, Pacira and Sanofi Biosurgery. Studied cell and molecular biology and genetics at the University of Maryland.

Neurogene chief medical officer with experience in gene therapy, rare disease and central nervous system clinical development. Previously chief medical officer at Homology Medicines and held clinical development roles at Cerevel, Avanir and Teva. Holds Harvard undergraduate and medical degrees and completed internal medicine training at Massachusetts General Hospital.

Neurogene chief scientific officer, leading scientific research and strategy since joining in 2019. A translational neuroscientist who also leads research at the University of Edinburgh, with earlier work at Glasgow. Holds a Glasgow BSc and Oxford neuroscience PhD.

President and chief financial officer of Neurogene and a board director, leading corporate strategy, business development, portfolio management, operations and finance. Joined Neurogene in 2019. Previously chief administrative officer, external business development leader and general counsel at Axovant Sciences. Holds Rutgers and Fordham law degrees.

Founder and chief executive officer of Neurogene and executive chair of its board. Founded the neurological gene therapy company in January 2018. Previously chief business and strategy officer at Intercept Pharmaceuticals and a biotechnology analyst. Holds a Cornell bachelor's degree and a Scripps Research Institute PhD, followed by a Berkeley Miller fellowship.

Medical-device entrepreneur and RiverVest consultant/venture partner in Tel Aviv. Former president of Boston Scientific’s cardiology business and a co-founder of multiple medical technology companies, including Velocimed; distinct from the Tectonic co-founder Michael Berman.

EcoR1 senior analyst evaluating biotechnology investments. Previously advised biotechnology clients on acquisitions and equity offerings at Goldman Sachs. Holds a Harvard neurobiology degree.

EcoR1 chief financial officer overseeing firm and fund accounting and finance. Previously worked at Sheffield Asset Management, Grosvenor Capital Management, Bank of America and Sunrise Capital Partners. Holds an Illinois finance degree.

EcoR1 partner, chief operating officer, general counsel and chief compliance officer responsible for operations, legal and compliance. Previously worked as a prosecutor and at Orrick and clerked at the Tenth Circuit. Holds a Berkeley law degree and Amherst bachelor's degree.

EcoR1 controller overseeing fund and firm accounting and finance. Previously worked at Agile Fund Solutions and Kaufman Rossin Fund Services. Holds a Ulyanovsk State University finance degree.

EcoR1 analyst evaluating biotechnology investments. Previously led a venture-backed biotechnology company. Holds a UCSF PhD and UC Berkeley studies in bioengineering, electrical engineering and computer science.

EcoR1 operations manager responsible for office administration and operations. Previously worked at the American Heart Association. Holds a College of Charleston finance degree.

EcoR1 investor relations associate. Previously advised biotechnology and pharmaceutical companies at Stern Investor Relations and worked with hospital systems at Cloudmed. Holds a UCLA human biology and society degree.

EcoR1 trader, previously a trader at Castle Hook Partners. Holds a Syracuse economics degree.

EcoR1 counsel responsible for legal and compliance matters. Previously worked as a litigation associate. Holds a UCLA law degree and University of Iowa English degree.

EcoR1 analyst evaluating biotechnology investment opportunities. Previously advised pharmaceutical and biotech companies on acquisitions and equity offerings at BofA Securities. Holds a Stanford economics degree.

EcoR1 partner investing in biotechnology. Previously worked in investment banking at Credit Suisse and served as chief investment officer of Panacea Acquisition Corp I and II. Holds a Georgetown economics degree with pre-medical study and a cognitive science minor.

EcoR1 executive personal assistant to partner Caroline Stout, with prior financial services executive support experience. Holds a UCLA Asian American studies degree.

EcoR1 principal evaluating biotechnology investments. Previously worked at Brace Pharma Capital. Holds a Virginia Tech biology degree and Georgetown biotechnology master's degree.

EcoR1 analyst evaluating biotechnology investment opportunities. Previously advised pharmaceutical and biotechnology companies at Deloitte. Holds natural sciences degrees with a chemistry specialization from Cambridge.

EcoR1 Capital founder and portfolio manager, establishing the biotechnology investment firm in 2013. Previously managed investments at BVF Partners. Holds a Georgetown science and technology-focused foreign service degree.

Sam Blackman is published by GV as Entrepreneur in Residence. A physician-scientist and pediatric neuro-oncologist working as entrepreneur in residence. Co-founded Day One Biopharmaceuticals and previously led its medical and drug-development organization.

Monique Schiersing is a Senior Investment Director at Roche Venture Fund. Bonum’s primary biography documents earlier RVF work during2009–2018, a period as Inthera Bioscience chief operating officer and investment experience at BankInvest. She also worked in Roche pharmaceutical business development. Holds a microbiology MSc from Zurich and an MBA from the University of San Francisco. Her existing Bonum board role is preserved; no personal cash investment is inferred.

Dewpoint board member and Leaps by Bayer senior director of venture investments, joining Leaps in 2026. Previously helped launch and lead Dana-Farber's Binney Street Capital and co-founded NextRNA Therapeutics. Holds a Union College mathematics degree and Mayo Clinic immunology PhD.

Dewpoint board member and Samsara BioCapital founder and managing general partner. Previously worked at Sofinnova Ventures, New Leaf Venture Partners, Panorama Capital, J.P. Morgan Partners and Genentech. Holds a Stanford medical degree and immunology PhD and Rice biochemistry and computer science degrees. Srinivas Akkaraju is listed by Samsara BioCapital as Founder & Managing Partner. Also known as Srini, he founded the platform after investment roles at Sofinnova, NewLeaf, Panorama and JPMorgan, and corporate-development work at Genentech. His education combines medicine, immunology, biochemistry and computer science.

Dewpoint board member and pharmaceutical executive. Former chief executive of Sanofi and Bayer HealthCare, with earlier leadership roles at Pfizer. Trained in infectious diseases and tropical medicine and holds biology and cellular immunology qualifications.

Dewpoint board member and MIT professor researching AI and health, natural language processing and deep learning applications in chemistry and oncology. An AI faculty lead at the Jameel Clinic, she holds a Columbia computer science PhD.

Dewpoint board member and structure-based drug design scientist. Co-founded Relay Therapeutics and previously served as Vertex Pharmaceuticals' chief technology officer. Contributed to medicines for HIV, hepatitis C, cystic fibrosis and glaucoma. Holds a Yale organic chemistry PhD.

Dewpoint board member and drug discovery scientist with experience in antiviral, immunology and biotherapeutics programs. Previously worked at Moderna, AstraZeneca, Boehringer Ingelheim and Pfizer. Holds a University College London biochemistry and molecular biology PhD.

Amir Nashat serves as Director at CAMP4 Therapeutics. CEO of Soufflé Therapeutics and entrepreneur partner at Polaris Partners, where he formerly served as managing partner. Also chairs Dewpoint’s board and has founded and financed biotechnology companies. Current Polaris entrepreneur partner in Boston and managing partner of Funds VI–IX. Joined in2002, is CEO of Soufflé Therapeutics and represents Polaris on healthcare boards, including CAMP4. Current entrepreneur-partner title is retained separately from fund-specific managing-partner responsibilities.

Richard Young serves as Director at CAMP4 Therapeutics. CAMP4 scientific co-founder and board director, also known as Rick Young. Whitehead Institute researcher and MIT biology professor studying gene control and cellular regulation; also a scientific founder and director of Dewpoint Therapeutics.

Dewpoint scientific co-founder and board member, also known as Tony Hyman. His research helped establish how phase separation creates biomolecular condensates and investigates their role in cellular organization and neurodegenerative diseases including ALS.

Dewpoint clinical development leader and physician-scientist specializing in oncology and hematology. Previously held development roles at Zai Laboratory, Sanofi and Merck. Holds a University of Pennsylvania medical degree and trained at Johns Hopkins and Beth Israel Deaconess.

Dewpoint early discovery leader, also known as Avi Patel, studying condensate disease biology and target discovery. His postdoctoral work with Tony Hyman investigated FUS condensates in ALS and the role of ATP in protein solubility and condensation.

Dewpoint head of finance and accounting. Previously led controllership functions at AskBio and Precision BioSciences and worked in corporate finance at MedImmune, Cisco and HP. Began his career as a Deloitte CPA and holds degrees from Babson and Bentley.

Dewpoint head of financial planning and analysis. Worked in financial services and healthcare before moving into life sciences, supporting the financial planning needs of drug discovery programs.

Dewpoint technology and corporate strategy leader working at the intersection of data science and healthcare R&D. Previously led biopharma AI projects at McKinsey and QuantumBlack and product teams at Genomics England. His PhD research combined computational modelling and experimental neuroscience to study spatial memory.

Dewpoint general counsel, head of corporate affairs and corporate secretary. Previously led the legal function at InVivo Therapeutics and worked on intellectual property and legal matters at Ecolab and PLR IP. Holds biochemistry and chemistry degrees, a law degree and a Harvard management master's degree.

Dewpoint chief scientific officer leading condensate-based research across oncology, neurology, cardiology and metabolic disease. Her work studies gene control, transcription factor phase separation and drug partitioning into condensates. Holds a Stockholm University biology PhD and trained at the Whitehead Institute.

Dewpoint chief development and operating officer, physician-scientist and medical oncologist working on condensate biology and therapeutic development. Previously worked at Dana-Farber, Harvard Medical School and the Whitehead Institute. Holds a Rockefeller immunology and genetics PhD and Weill Cornell medical degree.

Dewpoint chief executive and board member, a physician and global drug developer. Previously held chief medical and chief digital officer roles at Sanofi and senior medical affairs and development roles at Novartis. Trained in cardiology and intensive care medicine and holds an MBA.

Mitchell Mutz is listed by Samsara BioCapital as Senior Principal. He joined in2025 after investing at Vivo and Roche. He co-founded Amplyx and helped establish Labcyte, bringing chemistry, drug-development and biotechnology entrepreneurship experience.

Anika Gupta is published by GV as Principal. A biotechnology investor and company builder with a bioinformatics research background. Earlier work included patient-stratification methods at Foundation Medicine and immunotherapy prediction at Merck; her own full name is Anika Gupta Vatsa.

Rami Hannoush is Versant Ventures’ current Venture Partner. Drug-discovery scientist and company-building venture partner with source-published therapeutic protein and small-molecule research experience. His earlier roles include Mubadala Capital healthcare general partner, EpiBiologics co-founder/CEO and Genentech therapeutic-modality research leadership. He holds a McGill chemistry doctorate and completed Harvard postdoctoral work.

Neural Galaxy co-founder and former president and CEO, also known as Coach Kecheng Wei. Previously co-founded venture-backed technology companies working on enterprise applications, cloud computing and artificial intelligence. Studied at Tsinghua University and MIT. His Neural Galaxy CEO role ended in April 2024 according to a 2026 court order.

Neural Galaxy co-founder and MIT neuroscientist. Director of the McGovern Institute and Doris and Don Berkey Professor in Brain and Cognitive Sciences, studying visual attention and neural communication. Previously directed the National Institute of Mental Health's intramural research program.

Neural Galaxy co-founder and chief scientist researching individualized brain functional architecture, computational neuroimaging and precision neuromodulation. His 2026 research disclosure also identifies him as a co-founder and chief scientist of Galaxy Brain Scientific. His work includes methods for personalized functional circuit mapping and neuromodulation targeting.